The statements below are read from Vanta Bioscience Limited’s filed results, 3 filed quarters and 8 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed May 31, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H2 FY25Mar 2025 | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|---|
| Sales | 0.93 | 0.30 | 1.51 | +62.3% |
| 4.81 | 0.67 | 0.13 | -97.4% | |
| Operating profit | -3.87 | -0.37 | 1.39 | n/m |
| OPM % | -415.1% | -122.2% | 91.6% | +506.8 pp |
| Other income | 0.07 | 0.00 | 0.16 | +125.0% |
| Interest | 1.92 | 0.88 | -0.11 | -105.5% |
| Depreciation | 2.73 | 0.61 | -0.23 | -108.3% |
| Profit before tax | -8.45 | -1.87 | 1.88 | n/m |
| Tax % | n/a (loss) | n/a (loss) | -2.5% | — |
| Net profit | -9.16 | -1.82 | 1.93 | n/m |
| EPS (₹) | -4.29 | -2.56 | 2.71 | n/m |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
